Pharmacokinetics of tedizolid in an obese patient after bariatric surgery

7Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) was 28.3 mg/liter · h. The AUC 0-24 /MIC ratio for unbound concentrations and for sensitive Staphylococcus and Streptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.

Cite

CITATION STYLE

APA

Grégoire, M., Libois, J. B., Waast, D., Gaborit, B., Dauty, M., Deslandes, G., … Couet, W. (2018). Pharmacokinetics of tedizolid in an obese patient after bariatric surgery. Antimicrobial Agents and Chemotherapy, 62(4). https://doi.org/10.1128/AAC.02432-17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free